Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 42

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 42
---
 compliance with the MVPHS Requirement. In the event the Company does not regain compliance with the above requirement prior to the
expiration of the compliance period, it will receive written notification that its securities are subject to delisting. Alternatively,
the Company may apply to transfer the Company’s securities to The Nasdaq Capital Market.

On November 21, 2024,
the Company received a notice from the Staff of Nasdaq notifying the Company that its securities are subject to delisting due to the
MVPHS Deficiency and MLVS Deficiency. The Company requested a hearing to appeal the delisting determination before the Nasdaq Hearings
Panel (the “Panel”) on November 27, 2024. On November 29, 2024, the Company received a formal notice from Nasdaq that the
Panel will consider its appeal at an oral hearing on January 28, 2025 (the “Hearing”). On February 19, 2025, the
Company received written decision from the Panel, which granted an extension, allowing the Company additional time to regain compliance
with the Nasdaq Stock Market’s (“Nasdaq” or the “Exchange”) continued listing requirements, subject to
meeting specific compliance criteria within designated timeframes. On February 11, 2025, the Company carried out a 1-for-20 reverse stock
split of its issued and unissued shares. The effect of the reverse stock split was to consolidate every 20 issued and unissued share
into one share. On February 27, 2025, the Company received a notification letter from Nasdaq, indicating that the closing bid price of
the Company’s securities had been at $1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February
26, 2025, and the Company had regained compliance with the Minimum Bid Price Rule. In addition, on February 27, 2025, the Company received
a confirmation from Nasdaq that its application to transfer its listing to the Nasdaq Capital Market had been approved and that the Company’s
securities would be transferred to the Nasdaq Capital Market at the opening of business on February 28, 2025. On March 10, 2025, the
Company received a confirmation letter from Nasdaq confirming that it has demonstrated compliance with all of Nasdaq’s listing
requirements, as required in the Panel’s decision letter dated February 19, 2025.

<div align='center'>27</